---
title: 'Second Primary Malignancies After Commercial CAR T Cell Therapy: Analysis
  of FDA Adverse Events Reporting System (FAERS)'
date: '2024-03-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38483155/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240315180553&v=2.18.0.post9+e462414
source: Blood
description: Second primary malignancies (SPMs) were reported in 536 out of 12,394
  (4.3%) adverse event reports following CAR T cell therapies in the FDA Adverse Event
  Reporting System (FAERS). Myeloid and T-cell neoplasms were disproportionately more
  frequently reported, warranting further ...
disable_comments: true
---
Second primary malignancies (SPMs) were reported in 536 out of 12,394 (4.3%) adverse event reports following CAR T cell therapies in the FDA Adverse Event Reporting System (FAERS). Myeloid and T-cell neoplasms were disproportionately more frequently reported, warranting further ...